GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of [Lab] Homopeptide survo — Medutest came back 98.4% against a claimed 98.0% — 61 comments in the full submission. View in context.
1.7k
c/survodutide·submitted 1 year ago by u/britt_abubakar

[Lab] Homopeptide survo — Medutest came back 98.4% against a claimed 98.0%

Questionbranch of 6 comments

Homopeptide survo — Medutest came back 98.4% against a claimed 98.0%. One vial, one service, one member paying, which is the only kind of result this board should treat as evidence. The relevant figures are 98.4% and 98.0%, and they come from the same log I have kept the whole time. Sent a vial to PeptideMeter…

Read the full submission and all 61 comments →

This branch

6 comments, started 1 year ago
u/liv_vukovic130 points·1 year ago

glucagon agonism and energy expenditure is the mechanistic thread

replysharereportpermalink
u/britt_abubakarOP76 points·1 year ago·edited

glucagon agonism and energy expenditure is the mechanistic thread

This is the framing the board needs. It is a hepatic programme first.

replysharereportpermalink
u/injection_site_iris49 points·1 year ago

Not convinced. Imaging-based fat fraction is not the same as a histological response and the paper is explicit about that.

replysharereportpermalink
u/hana_pereira41 points·1 year ago

This. Biopsy-confirmed and imaging-suggested are different evidentiary categories and get run together constantly.

replysharereportpermalink
u/mod_cold_roommod · c/coldchain71 points·1 year ago

glucagon agonism and energy expenditure is the mechanistic thread

Agreed — and the endpoint definitions are where the actual claim lives.

replysharereportpermalink
u/nadia_bakker58 points·1 year ago

Careful with the mechanism claim. Glucagon agonism is plausible as an explanation and it has not been isolated as the operative one.

replysharereportpermalink

← back to the whole thread

About c/survodutide

Survodutide-specific discussion: glucagon-receptor co-agonism, the hepatic fat and MASH resolution data, and how the side-effect profile compares with GIP-based dual agonism. Small community, high signal.

12kmembers
62submissions
Feb 2024created
submissions / month, last year
Sponsored

Sigma-Aldrich Standards

Certified reference materials for peptide identity and purity work.

sigmaaldrich.com
More in c/survodutide
c/survodutide rules
  1. Glucagon co-agonism has a distinct safety story. Do not generalise from tirzepatide.
  2. MASH claims need the trial and the biopsy endpoint.
  3. Not approved. Descriptive posts only.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/incretin_ivyu/liver_enzyme_lizu/trialwatch_theo
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →